Ana Marie Dizon, MD
Endocrinology, Diabetes & Metabolism · Virginia Beach, VANPI 1245280114
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by AstraZeneca at 57.3% of the total. Reporting peaked in 2019 at $4,890 and has fallen 67.1% since, to $1,608 in 2025.
Across 211 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Medtronic$1K
- Novo Nordisk$628
- Amgen$349
- Lilly USA, LLC$268
- AbbVie$219
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$5,35055%
- Travel & lodging$6997%
- Food & beverage$3,43035%
- Education$2763%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $5,589 |
| Medtronic | 17 | $1,402 |
| Novo Nordisk | 56 | $628 |
| Amgen(2 entities) | 29 | $349 |
| Lilly USA, LLC | 14 | $268 |
| AbbVie | 15 | $219 |
| Boehringer Ingelheim | 13 | $209 |
| Dexcom, Inc. | 8 | $174 |
| Pfizer | 4 | $88 |
| Xeris Pharmaceuticals, Inc. | 4 | $84 |
| Corcept Therapeutics | 4 | $83 |
| Zealand Pharma US, Inc. | 4 | $76 |
| Mannkind Corporation | 2 | $67 |
| Radius Health, Inc. | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| BETA Bionics, Inc. | 6 | $49 |
| Amarin Pharma, Inc. | 2 | $45 |
| Insulet Corporation | 2 | $44 |
| IBSA Pharma Inc. | 2 | $42 |
| Vistapharm, Inc. | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $30 |
| BD | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $21 |
| Novartis | 1 | $19 |
| Bayer | 1 | $17 |
| Intuity Medical Inc | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$5,452
- MINIMED 780G$853
- InPen$120
How this compares
$9,755 in reported general payments places this provider in the 85th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $125,949 |
| TrulicityDulaglutide | 49 | $100,820 |
| JardianceEmpagliflozin | 58 | $78,820 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $65,542 |
| FarxigaDapagliflozin Propanediol | 47 | $55,476 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $30,784 |
| JanuviaSitagliptin Phosphate | 22 | $25,921 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $17,551 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 13 | $6,449 |
| NovologInsulin Aspart | 11 | $5,553 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $4,865 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,634 |
| SynthroidLevothyroxine Sodium | 42 | $3,543 |
| Levothyroxine Sodium | 219 | $2,112 |
| Methimazole | 60 | $751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $628 | $131,50193 claims |
| Lilly USA, LLCTrulicity | $268 | $100,82049 claims |
| Boehringer IngelheimJardiance | $209 | $78,82058 claims |
| AstraZenecaFarxiga | $5,589 | $55,47647 claims |
| AbbVieSynthroid | $219 | $3,54342 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $30 | $2,444232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Virginia Beach
- Howard HarrisonVirginia Beach$20K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.